

Datasheet: HCA262P

Description:	HUMAN ANTI PALIVIZUMAB:HRP
Specificity:	PALIVIZUMAB
Other names:	SYNAGIS®
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD23967_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml
Immunogen	Palivizumab

Specificity **Human anti Palivizumab, clone AbD23967_hIgG1**, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.

Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 ([HCA261](#)) in monovalent Fab format.

Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.

[View a summary of all anti-palivizumab antibodies](#)

Affinity The intrinsic affinity of the monovalent form of this antibody is $K_D=1.5$ nM as measured by real time, label-free molecular interaction analysis on immobilized Palivizumab.

ELISA This product may be used as a detection reagent in a sandwich ELISA together with [HCA261](#) as the capture reagent.
Protocol: [PK bridging ELISA to measure free drug](#).

References 1. Kashiwagi, N. *et al.* (2017) Method for measuring anti-drug antibody [US Patent Application US20170315118A1](#)

Storage This product is shipped frozen.
When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.

Guarantee 12 months from date of despatch

Acknowledgements This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Synagis is a trademark of the AstraZeneca group of companies.

Health And Safety Information Material Safety Datasheet documentation #10094 available at: <https://www.bio-rad-antibodies.com/SDS/HCA262P>

10094

Licensed Use For *in vitro* research purposes and for commercial applications for the provision of *in vitro* testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

[HUMAN ANTI PALIVIZUMAB \(HCA261\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI PALIVIZUMAB \(HCA262\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M430232:240503'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)